Metraipolis › archive › dc_682fceebb53a

STAT3 inhibitor in oncology: a trial-based analysis of translational challenges and evolving therapeutic paradigms — Europe PMC PMID:42180089

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42180089
DOI: 10.3389/fonc.2026.1802640
License (as archived): solo-consultazione
Archived: 2026-11-02T16:03:03.163Z
SHA-256 of the archived text: ee60f3368f7dc0760ea6d54d5196cc0d029f6d45eeaf257ef0a7a2f473380bb9
Stable URL of this page: https://metraipolis.com/documento/dc_682fceebb53a

How to cite

STAT3 inhibitor in oncology: a trial-based analysis of translational challenges and evolving therapeutic paradigms — Europe PMC PMID:42180089 — Europe PMC (en), https://europepmc.org/article/MED/42180089 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_682fceebb53a (Metraipolis archive dc_682fceebb53a, sha256 ee60f3368f7dc0760ea6d54d5196cc0d029f6d45eeaf257ef0a7a2f473380bb9)

BibTeX

@misc{dc682fceebb53a,
  title = {STAT3 inhibitor in oncology: a trial-based analysis of translational challenges and evolving therapeutic paradigms — Europe PMC PMID:42180089},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42180089},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_682fceebb53a; sha256 ee60f3368f7dc0760ea6d54d5196cc0d029f6d45eeaf257ef0a7a2f473380bb9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42180089. Agents can read the archived copy with the MCP tool read_document.